



**Chrysos Corporation Limited**  
ACN 613 131 141  
**SUPPLEMENTARY PROSPECTUS**

## 1. IMPORTANT NOTICE

This Supplementary Prospectus contains particulars of changes to, and supplements, the prospectus dated 14 April 2022 (**Prospectus**) issued by Chrysos Corporation Limited ACN 613 131 141 (**Company**) and Chrysos Sale Co Limited ACN 657 974 377 (**SaleCo**) offering fully paid ordinary shares in the Company.

This Supplementary Prospectus is dated 22 April 2022 and was lodged with the Australian Securities and Investments Commission (**ASIC**) on that date. Neither ASIC nor the Australian Securities Exchange (**ASX**) take any responsibility as to the contents of this Supplementary Prospectus.

This Supplementary Prospectus must be read together with the Prospectus. To the extent of any inconsistency between this Supplementary Prospectus and the Prospectus, the provisions of this Supplementary Prospectus will prevail. Unless otherwise indicated, terms defined and used in the Prospectus have the same meaning in this Supplementary Prospectus. The Important Information section of the Prospectus applies to this Supplementary Prospectus to the extent relevant.

This Supplementary Prospectus will be available in electronic form on <https://www.chrysos.com.au/prospectus>, with hard copies available by calling the Offer Information Line on 1800 677 648 (if calling within Australia) or +61 1800 677 648 (if calling from outside of Australia) from 8.30am to 5.30pm (Sydney time) Monday to Friday.

This Supplementary Prospectus and the Prospectus are important documents that should be read together, in their entirety. If you have any questions about the Shares being offered under the Prospectus or any other matter, you should consult your professional advisors.

This Supplementary Prospectus does not constitute an offer or invitation in any place in which, or to any person to whom, it would not be lawful to make such an offer or invitation. No action has been taken to register or qualify the Shares or the Offer, or to otherwise permit a public offering of Shares, in any jurisdiction outside Australia.

The distribution of this Supplementary Prospectus outside Australia (including electronically) may be restricted by law and persons who come into possession of the Supplementary Prospectus outside Australia should seek advice and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. For details of selling restrictions that apply to the Shares in certain jurisdictions outside of Australia, please refer to Section 8.12 of the Prospectus.

The Shares have not been, and will not be, registered under the U.S. Securities Act and may not be offered or sold in the United States of America, or to, or for the account or benefit of, "U.S. Persons" (as defined in Rule 902 under the U.S. Securities Act) except under an available exemption from registration under the U.S. Securities Act. The Shares may only be resold or transferred in the United States of America, or to, or for the account or benefit of, U.S. Persons if registered under the U.S. Securities Act or pursuant to an exemption from registration under the U.S. Securities Act and in compliance with state securities laws. The Company is under no obligation and has no intention to register any of the Shares in the United States of America.

Chrysos Corporation Limited  
ABN 76 613 131 141

Waite Campus,  
Waite Road,  
URRBRAE, SA, 5064  
Australia

**E** [investors@chrysos.com.au](mailto:investors@chrysos.com.au)  
**W** [www.chrysos.com.au](http://www.chrysos.com.au)



## 2. ADDITIONAL DISCLOSURE

The purpose of this Supplementary Prospectus is to provide additional disclosure in relation to the process undertaken by the Directors of Chrysos to estimate Total Contract Value.

### Section 1.3 Key Statistics and Business Highlights

Footnote 6 currently reads:

*TCV represents the future minimum contracted revenue on PhotonAssay leases (both deployed and committed) that are yet to be invoiced at a point in time, which are subject to the Company's contractual performance obligations and where the Directors consider reasonable certainty exists, may include values associated with exercise of option periods.*

The following text is added to footnote 6:

*Of the 33 units either deployed or committed at Prospectus date, the Directors' estimate is that 65% of PhotonAssay unit contracts include the renewal of a single option period, with the balance assumed to have a duration equivalent to the initial contract term.*

### Section 4.2.4 Explanation of Non-IFRS Financial Measures

The third bullet point under the Operating metrics section currently reads:

**Total contract value (TCV):** *represents the future minimum contracted revenue on PhotonAssay leases (both deployed and committed) that are yet to be invoiced at a point in time, which are subject to the Company's contractual performance obligations and where the Directors consider reasonable certainty exists, may include values associated with exercise of option periods.*

The following text is added to the third bullet point under the Operating metrics section:

*Where assessing the inclusion of option periods, the Directors consider variables including, but not limited to, counter party risk, the site application, life of associated mine, client history, renewal activity, investment by the counter party in the provision of PhotonAssay, competitor threats, PhotonAssay versus Fire Assay activity, site specific conditions and location of the unit. The TCV does not include any period in excess of 10 years from initial deployment of a PhotonAssay unit.*

## 3. CONSENTS

The Company confirms that as at the date of this Supplementary Prospectus, each of the parties that have been named as having consented to being named in the Prospectus have not withdrawn that consent.

## 4. DIRECTORS' AUTHORISATIONS

This Supplementary Prospectus has been authorised by each Director and each director of SaleCo. Each Director and director of SaleCo has consented to its lodgement with ASIC and its issue and has not withdrawn that consent.

Dated: 22 April 2022

Signed for and on behalf of Chrysos Corporation Limited and Chrysos Sale Co Limited

**Robert Adamson**  
Chairman